Literature DB >> 12383504

Molecular features of human ubiquitin-like SUMO genes and their encoded proteins.

Hong-Lin Su1, Steven S-L Li.   

Abstract

The SUMO (small ubiquitin-like modifier) protein and ubiquitin have similar 3-D structure. Sumolyzation and ubiquitination exhibit similar biological processes for post-translational modification. However, unlike ubiquitination, which targets proteins for degradation, sumolyzation participates in a number of cellular processes such as nuclear transport, transcriptional regulation, apoptosis and protein stability. The human genome contains three SUMO-1/2/3 functional genes, as well as eight SUMO-1 pseudogenes and 23 SUMO-2 pseudogenes, but no SUMO-3 pseudogenes. The protein-coding sequence of the SUMO-1 gene is interrupted by four introns, while those of SUMO-2 and SUMO-3 genes are interrupted by three introns. Human SUMO-1 protein exhibits 44% sequence identity with SUMO-2 and SUMO-3 proteins, while SUMO-2 and SUMO-3 proteins share 86% sequence identity. Phylogenetic analyses indicate that the SUMO-3 gene was derived from the SUMO-2 gene. SUMO-1 mRNA appears to be most abundant in human epithelial HeLa, kidney 293 and neuronal NT2 cells, while the SUMO-3 mRNA seems to be much less abundant than SUMO-2 mRNA, especially in HeLa and 293 cells. Many cellular proteins of high molecular weights were covalently modified by SUMO-1/2/3 proteins. However, some free form of SUMO-2/3 proteins was also detected. Most SUMO-1/2/3 proteins were shown to be localized on nuclear membrane, nuclear bodies and cytoplasm, respectively.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12383504     DOI: 10.1016/s0378-1119(02)00843-0

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  52 in total

1.  Small ubiquitin-like modifier (SUMO) modification mediates function of the inhibitory domains of developmental regulators FOXC1 and FOXC2.

Authors:  Theodora E Danciu; Sergey Chupreta; Osvaldo Cruz; Jennifer E Fox; Malcolm Whitman; Jorge A Iñiguez-Lluhí
Journal:  J Biol Chem       Date:  2012-04-05       Impact factor: 5.157

2.  Up-regulation of SUMO1 pseudogene 3 (SUMO1P3) in gastric cancer and its clinical association.

Authors:  Danyi Mei; Haojun Song; Kai Wang; Yichao Lou; Weiliang Sun; Zhong Liu; Xiaoyun Ding; Junming Guo
Journal:  Med Oncol       Date:  2013-09-01       Impact factor: 3.064

3.  The role of post-translational modifications of huntingtin in the pathogenesis of Huntington's disease.

Authors:  Yan Wang; Fang Lin; Zheng-Hong Qin
Journal:  Neurosci Bull       Date:  2010-04       Impact factor: 5.203

4.  Mapping residues of SUMO precursors essential in differential maturation by SUMO-specific protease, SENP1.

Authors:  Zheng Xu; Shannon W N Au
Journal:  Biochem J       Date:  2005-03-01       Impact factor: 3.857

Review 5.  SUMO wrestling with type 1 diabetes.

Authors:  Manyu Li; Dehuang Guo; Carlos M Isales; Decio L Eizirik; Mark Atkinson; Jin-Xiong She; Cong-Yi Wang
Journal:  J Mol Med (Berl)       Date:  2005-04-02       Impact factor: 4.599

6.  A small conserved surface in SUMO is the critical structural determinant of its transcriptional inhibitory properties.

Authors:  Sergey Chupreta; Sam Holmstrom; Lalitha Subramanian; Jorge A Iñiguez-Lluhí
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

Review 7.  Neurodegeneration and neuroprotection in Parkinson disease.

Authors:  Stanley Fahn; David Sulzer
Journal:  NeuroRx       Date:  2004-01

8.  The SUMO E3 ligase activity of Pc2 is coordinated through a SUMO interaction motif.

Authors:  Shen-hsi Yang; Andrew D Sharrocks
Journal:  Mol Cell Biol       Date:  2010-02-22       Impact factor: 4.272

9.  SUMO-mediated inhibition of glucocorticoid receptor synergistic activity depends on stable assembly at the promoter but not on DAXX.

Authors:  Sam R Holmstrom; Sergey Chupreta; Alex Yick-Lun So; Jorge A Iñiguez-Lluhí
Journal:  Mol Endocrinol       Date:  2008-06-18

10.  SUMOylation of Vps34 by SUMO1 promotes phenotypic switching of vascular smooth muscle cells by activating autophagy in pulmonary arterial hypertension.

Authors:  Yufeng Yao; Hui Li; Xinwen Da; Zuhan He; Bo Tang; Yong Li; Changqing Hu; Chengqi Xu; Qiuyun Chen; Qing K Wang
Journal:  Pulm Pharmacol Ther       Date:  2019-01-28       Impact factor: 3.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.